Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Incobotulinum Toxin A (Xeomin®) for Focal Task-Specific Dystonia of the Musician's Hand
NCT02107261Phase 2Completed
- Sponsor
- Icahn School of Medicine at Mount Sinai
- Start
- Mar 2014
- Primary completion
- Jan 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of incobotulinumtoxinA in focal task-specific dystonia (TSD), sponsored by Icahn School of Medicine at Mount Sinai. Started Mar 2014; status: completed.
02
Drugs
incobotulinumtoxinA
03
Conditions
focal task-specific dystonia (TSD)
Beyond the preview
Go deeper on NCT02107261.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02107261.